PURPOSE: This study aimed to understand the prognostic value of integrin β1 expression in head and neck squamous cell carcinoma (HNSCC) and the mechanism underlying its association with metastatic HNSCC. EXPERIMENTAL DESIGN: Archival HNSCC tissues including 99 nonmetastatic primary tumors and 101 metastatic primary tumors were examined for the association of integrin β1 expression with metastasis and disease prognosis by appropriate statistical methods. Fluorescence-activated cell sorting was used to separate the integrin β1(high/+) cell population from the integrin β1(low/-) population in HNSCC cell lines. These two populations and integrin β1 shRNA knockdown HNSCC cells were examined for the effect of integrin β1 on invasion in vitro and on lymph node and lung metastases in a xenograft mouse model. Expression and activation of matrix metalloproteinases (MMP) were examined by zymography. RESULTS: Statistical analysis showed that integrin β1 expression was significantly higher in the metastatic primary tumors than in the nonmetastatic tumors (42.6% vs. 24.8%, P < 0.0001 and P < 0.0001 by univariate and multivariate analyses, respectively). In patients with lymph node metastasis, integrin β1 expression was inversely correlated with overall survival (P = 0.035). The integrin β1 knockdown or integrin β1(low/-) HNSCC cells showed a significant reduction in lymph node and lung metastases in vivo (P < 0.001 and P < 0.05, respectively). Significantly reduced Matrigel invasion capability was also found in integrin β1 knockdown or integrin β1(low/-) HNSCC cells (P < 0.01). Finally, zymography results showed integrin β1-affected HNSCC invasion by regulating MMP-2 activation. CONCLUSION: These findings indicate that integrin β1 has a major impact on HNSCC prognosis through its regulation of metastasis.
PURPOSE: This study aimed to understand the prognostic value of integrin β1 expression in head and neck squamous cell carcinoma (HNSCC) and the mechanism underlying its association with metastatic HNSCC. EXPERIMENTAL DESIGN: Archival HNSCC tissues including 99 nonmetastatic primary tumors and 101 metastatic primary tumors were examined for the association of integrin β1 expression with metastasis and disease prognosis by appropriate statistical methods. Fluorescence-activated cell sorting was used to separate the integrin β1(high/+) cell population from the integrin β1(low/-) population in HNSCC cell lines. These two populations and integrin β1 shRNA knockdown HNSCC cells were examined for the effect of integrin β1 on invasion in vitro and on lymph node and lung metastases in a xenograft mouse model. Expression and activation of matrix metalloproteinases (MMP) were examined by zymography. RESULTS: Statistical analysis showed that integrin β1 expression was significantly higher in the metastatic primary tumors than in the nonmetastatic tumors (42.6% vs. 24.8%, P < 0.0001 and P < 0.0001 by univariate and multivariate analyses, respectively). In patients with lymph node metastasis, integrin β1 expression was inversely correlated with overall survival (P = 0.035). The integrin β1 knockdown or integrin β1(low/-) HNSCC cells showed a significant reduction in lymph node and lung metastases in vivo (P < 0.001 and P < 0.05, respectively). Significantly reduced Matrigel invasion capability was also found in integrin β1 knockdown or integrin β1(low/-) HNSCC cells (P < 0.01). Finally, zymography results showed integrin β1-affected HNSCC invasion by regulating MMP-2 activation. CONCLUSION: These findings indicate that integrin β1 has a major impact on HNSCC prognosis through its regulation of metastasis.
Authors: J A Martignetti; A A Aqeel; W A Sewairi; C E Boumah; M Kambouris; S A Mayouf; K V Sheth; W A Eid; O Dowling; J Harris; M J Glucksman; S Bahabri; B F Meyer; R J Desnick Journal: Nat Genet Date: 2001-07 Impact factor: 38.330
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Xin Zhang; Yanna Liu; Michael Z Gilcrease; Xiao H Yuan; Gary L Clayman; Karen Adler-Storthz; Zhuo Chen Journal: Cancer Date: 2002-10-15 Impact factor: 6.860
Authors: Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen Journal: Clin Cancer Res Date: 2016-06-29 Impact factor: 12.531
Authors: Ning Jiang; Dongsheng Wang; Zhongliang Hu; Hyung Ju C Shin; Guoqing Qian; Mohammad Aminur Rahman; Hongzheng Zhang; A R M Ruhul Amin; Sreenivas Nannapaneni; Xiaojing Wang; Zhengjia Chen; Gabriela Garcia; Gavin MacBeath; Dong M Shin; Fadlo R Khuri; Jun Ma; Zhuo G Chen; Nabil F Saba Journal: Mol Cancer Ther Date: 2014-04-18 Impact factor: 6.261